Rakovina Therapeutics Inc. announces its shares are now eligible for electronic clearing and settlement through The Depository Trust Company (DTC), enhancing liquidity and market accessibility for U.S. investors. This move supports Rakovina’s goal of increasing visibility and engagement with institutional and retail investors, removing barriers to efficient trading in the U.S. and supporting long-term shareholder value. The company continues to advance preclinical programs and explore partnerships in AI-enhanced diagnostics and oncology therapeutics, with more developments expected. Rakovina focuses on developing innovative cancer treatments using AI-powered drug discovery technologies, aiming to advance drug candidates into human clinical trials with pharmaceutical partners.

Read more at GlobeNewswire: Rakovina Therapeutics Granted DTC Eligibility to Expand